Refine by
Genomic Data Articles & Analysis
48 news found
By achieving two new certifications, SOPHiA GENETICS further solidifies its commitment to protecting the data of its customers and complying with global data protection regulations. ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that Tennessee Oncology, one of the United States’ largest community-based cancer care specialists that treats nearly half of Tennessee’s cancer patients across 35 clinics, has expanded its relationship with SOPHiA GENETICS to advance its ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven medicine, today announced the next step in the partnership between the Company and Genomenon, a leading genomic intelligence company, to support better, data-driven outcomes in the rare disease and oncology fields. ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, will unveil new research at the European Society for Medical Oncology (ESMO) 2024. ...
These institutions include renowned cancer centers and reference laboratories such as: BioReference® and Tennessee Oncology in the U.S.; Oncohelix in Canada; Dasa in Brazil; Universitätsklinikum Heidelberg in Germany; Stavanger University Hospital in Norway; IUCT Oncopole in France; Synnovis and South West Genomic Laboratory Hub, operating out of North Bristol NHS Trust ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that the company is joining the European Liquid Biopsy Society (ELBS), a prestigious network consisting of partners from academia and industry with the common goal of making liquid biopsy tests part of the routine standard of care. ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update from the Company’s work with biopharma company Boundless Bio. ...
Data computed daily by the Platform has surged over the years with over 1.8 million genomic profiles being analyzed on the platform, at a rate of almost 30,000 analyses per month. ...
Parameters such as Contig N50 and Scaffold N50 describe the "completeness" of a genome assembly. EST datasets, RNA sequences, or conserved genes are used to evaluate completeness, while BAC data tests accuracy. For hyper repetitive and heterozygous regions, CD Genomics combines data from HiSeq, PacBio, and Sanger sequencing to ...
High-Throughput and High-Quality Data: CD Genomics is steadfast in its commitment to delivering data of the highest quality and throughput. ...
CD Genomics, a prominent leader in the next generation sequencing arena, proudly announce the launch of a groundbreaking 5mC/5hmC sequencing service. ...
CD Genomics, an excellent leader in genomics and bioinformatics, has unveiled a groundbreaking leap forward in TCR-Seq technology, poised to revolutionize immune repertoire profiling. ...
This state-of-the-art technology enables scientists to pinpoint and characterize actively degrading RNA molecules, shedding new light on essential regulatory mechanisms. Key Highlights of CD Genomics' Degradome Sequencing Service: High-Precision Data: CD Genomics employs a cutting-edge sequencing platform that produces high-precision ...
CD Genomics, a trailblazing genomics and bioinformatics services provider, is delighted to announce the launch of the Long Amplicon Analysis (LAA) service, a mature genomic research method that promises to revolutionize the field. ...
SeqOne Genomics, provider of nextgeneration genomic analysis solutions for personalized medicine, announces the appointment of Hervé Pouzoullic as Chief Commercial Officer (CCO). ...
” Cellworks Precision Drug Development: Pre-clinical Stage Biomarker Development: Cellworks uses cell line data and retrospective patient data to discover novel biomarkers for investigational agents, which can improve drug success rates by prospectively identifying patients who will respond to an agent. ...
The combination of existing IP and expertise in areas such as genomic data management, variant interpretation, NGS data quality control, and precision oncology, was fundamental to the partnership being awarded the contract. ...
” Cellworks Therapy Biosimulation The Cellworks Platform biosimulates how a patient's personalized genomic disease model will respond to therapies prior to treatment and can also identify novel drug combinations for treatment-refractory patients. ...
The Bioinformatics-Analysis, a subdivision of CD Genomics, provides reliable next-generation and third-generation high-throughput sequencing data analysis, comprehensive technology services, database construction, and other related data analysis services. CD Genomics provides metatranscriptome sequencing data ...
“Personalized medicine needs personalized data, and it is through collaborations like these that will allow us to offer more people in more regions of the world with genomic solutions,” said Andrea Riposati, CEO of Dante Genomics. ...